It has been estimated that germline mutations in BRCA2 account for about 5% of prostate cancer in familial clusters[15,16] However, other than the founder mutation in Iceland and possibly another mutation in those with Ashkenazi Jewish ancestry, the role of segregating BRCA2 mutations in familial prostate cancer remains unclear. This evidence concerns the gene BRCA2 and prostate cancer, hereditary.